Introduction
Adenocarcinoma of the pancreas represents the fifth leading cause of cancer death in Western countries (Greenlee et al., 2001) . As a result of a largely asymptomatic progress of the disease, only 10-15% of the patients have a tumor localized to the pancreas at the time of diagnosis allowing a potentially curative resection (Warshaw et al., 1990; Rosewicz and Wiedenmann, 1997) . Besides this surgical therapy, there are chemotherapy and radiation regimens that largely failed to improve the outcome of pancreatic cancer patients, and approximately 90% of patients still die within 1 year of diagnosis (Rosewicz and Wiedenmann, 1997) . Gemcitabine (difluorodeoxycytidine) is a relatively new agent with promising activity in solid tumors (Hui and Reitz, 1997) . Currently, this nucleoside analogue appears to be the only clinically active drug in the therapy of pancreatic cancer (Burris et al., 1997) . However, even with this drug most of pancreatic adenocarcinomas exhibit an inexorable disease progression, and treatment of the patients with gemcitabine provides only a slight survival advantage (Burris et al., 1997) . This is because of pre-existing or acquired chemoresistance in most of the tumor cells (Rosenberg, 1997) . Beside the 'classical' resistance mechanisms including insufficient intracellular concentration of the cytotoxic drug by defective activation/degradation pathways (Ruiz van Haperen et al., 1995; Dumontet et al., 1999) , altered interactions with intracellular targets (Goan et al., 1999) or an increased expression of detoxification mechanisms such as MDR-genes and antioxidants (Goldstein et al., 1989) , multiple mutations and changes in the expression of tumor supressor genes, proto-oncogenes and antiapoptotic genes occur at very high frequency in pancreatic cancer (Kalthoff et al., 1993; Moore et al., 2001; Crnogorac-Jurcevic et al., 2002) . Since these alterations and the mechanisms mentioned so far are also common to other malignancies, they are unlikely to be the major cause of the high level of chemoresistance seen in pancreatic cancer patients.
Two potential anti-apoptotic signal transduction pathways that have been linked to chemoresistance of pancreatic carcinoma cell lines are the PI3K/Akt- (Ng et al., 2000 (Ng et al., , 2001 and the NF-kB-pathway (Wang et al., 1999a, b; Dong et al., 2002; Arlt et al., 2001 .
By activating the phosphoinositide-dependent kinase-1 and recruiting the serine/threonine kinase Akt to the plasma membrane, PI3 K leads to the phosphorylation of Thr308 of Akt (Vanhaesebroeck et al., 2001 ). This phosphorylation is sufficient for Akt activation, but for a maximal Akt activity an additional phosphorylation of the Ser473 residue is required (Alessi et al., 1997) . Besides the growth promoting potential of Akt, its anti-apoptotic properties are closely linked to the resistance of cancer cells to a broad spectrum of apoptotic stimuli. The mechanisms by which Akt promotes cell survival under treatment with cytotoxic drugs include phosphorylation and thereby inactivation of pro-apoptotic proteins such as BAD, caspase-9 and members of the Forkhead family of transcription factors (reviewed in Vivanco and Sawyers, 2002) . In addition to the direct inhibition of pro-apoptotic mediators, Akt seems to be involved in the activation of antiapoptotic pathways such as the NF-kB signalling pathway. Recent reports have demonstrated that the PI3K/Akt pathway provides chemoresistance, at least in part, by the activation of NF-kB (Madrid et al., 2000; Reddy et al., 2000) .
NF-kB is a ubiquitiously expressed transcription factor that is involved in a wide spectrum of cellular functions like cell cycle control, stress adaptation, inflammation and control of apoptosis. NF-kB exists as a homo-or heterodimer of five members of the mammalian Rel/NF-kB family: p65/RelA, RelB, c-Rel, NF-kB1/p50 and NF-kB2/p52 (reviewed in Ghosh et al., 1998) . NF-kB, predominately existing as p65/p50 heterodimer, is retained in the cytoplasm by inhibitory proteins, with IkBa being the most abundant. A great variety of stimuli lead to activation of the IkB kinase (IKK) complex that phosphorylates two serine residues (Ser32 and 36) in the N-terminal domain of IkBa, followed by its polyubiquitination and subsequent degradation by the 26S proteasome. The released NFkB heterodimer then enters the nucleus and regulates gene expression.
NF-kB plays an important role in oncogenesis and promotes cellular resistance to anticancer therapy. Recently, it has been shown that NF-kB inhibition blocks cellular transformation by several viral oncoproteins. The fact that several lymphoid neoplasms show chromosomal alterations of NF-kB family genes provided additional evidence for the role of NF-kB in oncogenesis (reviewed in Rayet and Gelinas, 1999) .
Still subject of controversial reports is whether basal or induced NF-kB activity is more important for chemoresistance of cancer cells (reviewed in , and it is not clear how this is determined by the type of cell and/or anticancer drug. In the present study, we elucidated the sensitivity of five human pancreatic adenocarcinoma cell lines to gemcitabine and investigated the involvement of PI3K/Akt and NF-kB in the resistance to this clinically relevant chemotherapeutic agent.
Results
Gemcitabine and VP16 induce high levels of apoptosis in T3M4 and PT45-P1, but not in BxPc-3, Capan-1 and PancTu-1 cells
To determine apoptotic cell death of the human pancreatic carcinoma cell lines BxPc-3, Capan-1, PancTu-1, T3M4 and PT45-P1 treated with various concentrations (0.02-20 mm) of gemcitabine for 24 h, annexin V labelling and subsequent FACS analysis were conducted. As shown in Figure 1a , T3M4 and PT45-P1 cells exhibited a strong increase in apoptotic cell number (51-54% specific apoptosis) after treatment with 0.04-20 mm gemcitabine. In contrast, PancTu-1 cells were much less sensitive (22-25% specific apoptosis) and BxPc-3 and Capan-1 cells were almost completely resistant (10-12% specific apoptosis). At a dose below 0.04 mm, the apoptotic effect of gemcitabine on the sensitive cell lines T3M4 and PT45-P1 declined (corresponding to an ED50 value of approx. 0.02 mm).
As we recently characterized the sensitivity of the majority of these cell lines towards treatment with 20 mm VP16 , gemcitabine-induced cell death Role of NF-jB and PI3K/Akt in gemcitabine resistance A Arlt et al was compared with VP16-induced cell death. As shown in Figure 1b , VP16 treatment at doses between 2 and 20 mm for 24 h significantly induced cell death (up to 50% specific apoptosis) in the sensitive cell lines, whereas at lower doses the death inducing effect of VP16 declined (corresponding to an ED50 value of approx. 0.2 mm).
Gemcitabine-resistant cells exhibited high basal NF-kB activity, while all cell lines exhibited gemcitabine-induced NF-kB activity in a dose-dependent fashion
To test whether NF-kB activity is involved in the gemcitabine resistance of the pancreatic cancer cell lines, we analysed the constitutive as well as the gemcitabine-induced NF-kB activity. BxPc-3 and Capan-1 cells exhibited a strong NF-kB activity as shown by EMSA ( Figure 2a ) and luciferase reporter gene assay (Figure 2b ). In PancTu-1 cells, this basal NF-kB activity was slightly lower and in the two highly sensitive cell lines T3M4 and PT45-P1 no or only a weak basal NF-kB-activity was detectable ( Figure 2a and b). Next, we analysed whether there is a correlation between drug-induced NF-kB activity and the sensitivity of the pancreatic carcinoma cell lines towards gemcitabine-induced cell death. As a positive control for cytotoxic-drug-induced NF-kB activity, we used 20 mm VP16 ) and compared the kinetics as well as the strength of NF-kB activity by EMSA and luciferase reporter gene assay.
At 20 mm, both drugs transiently induced NF-kB binding activity in all cell lines as shown by EMSA ( Figure 3a ). The induction of NF-kB by gemcitabine was slightly lower and delayed in comparison with VP16 treatment (Figure 3a) . The maximal induction seen with both drugs occurred 5-6 h after drug administration. Supershift analysis indicated that the NF-kB activity induced by gemcitabine was composed of the p50 and p65 subunits (data not shown).
We next analysed the dose response of gemcitabineinduced NF-kB activity. For this purpose, cells were treated with 0.02-20 mm gemcitabine for 6 h. EMSAs and luciferase reporter gene assays showed that the levels of induced NF-kB binding activity and transcriptional activity, respectively, declined if the dose of gemcitabine was reduced. As shown in Figure 3b and c, NF-kB induction no longer occured at a dose of 0.04 mm, notably a dose inducing apoptosis with similar efficacy as 20 mm gemcitabine ( Figure 1a ).
NF-kB inhibition sensitized chemoresistant cells towards gemcitabine treatment
With respect to the main signalling pathway leading to NF-kB activation, three strategies for NF-kB inhibition were applied. In order to block the phosphorylation of the inhibitor kB (IkB), the IkB kinase inhibitor sulfasalazine (Weber et al., 2000) was used. To prevent proteasome-dependent degradation of IkB, the cells were incubated with the proteasome inhibitor MG132 (Grisham et al., 1999) . Additionally, for specific NF-kB inhibition the resistant cells were transfected with the IkBa super repressor, thereby imposing irreversible repression of NF-kB .
As shown by EMSA ( Figure 4a ) and luciferase reporter gene assay (Figure 4b ), incubation of BxPc-3, Capan-1 and PancTu-1 cells with sulfasalazine (1 mm) or MG132 (5 mm) for 3 h attenuated the basal NF-kB activity. Furthermore, pre-incubation with one of these inhibitors for 0.5 h abolished the NF-kB induction by 20 mm gemcitabine in all cell lines (data not shown). In addition, the transfection with the IkBa super repressor lowered the basal NF-kB activity if compared with mock-transfected cells (Figure 4c and d). The degree of NF-kB inhibition by the IkBa super repressor was sligthly lower in comparison with the pharmacological inhibitors, probably because of the limited transfection efficacy.
In order to analyse whether the basal or gemcitabineinduced NF-kB activity was involved in the resistance of BxPc-3, Capan-1 and PancTu-1 cells, NF-kB inhibition was carried out as descibed above and cells were subsequently treated for 24 h with a dose (0.04 mm) of gemcitabine that still induces apoptotic cell death in the sensitive cells (see above) but does not induce NF-kB activity.
Annexin V staining revealed that under these conditions of inhibited NF-kB activation, the chemoresistant cell lines became much more sensitive towards the treatment with gemcitabine ( Figure 5 ). In resistant BxPc-3 and Capan-1 cells, the weak apoptotic response (approximately 10%) was Figure 2 Constitutive NF-kB activitiy in human pancreatic cancer cell lines. (a) Nuclear extracts from untreated pancreatic cancer cell lines were prepared and EMSAs for NF-kB binding activity were performed. A representative from four independent experiments is shown. (b) Cells were transfected with pNFkBLuc(firefly) together with pTKLuc(renilla). At 16 h after transfection, the medium was replaced and cells were left untreated for further 6 h. Expression of firefly-luciferase and renilla-luciferase in total cellular extracts (adjusted to equal amounts of protein) was measured. Fireflyluciferase activity was normalized to the amount of renillaluciferase and the data represent the mean (+/À s.d.) of four independent experiments performed in duplicates Role of NF-jB and PI3K/Akt in gemcitabine resistance A Arlt et al strongly enhanced in the presence of MG132 (36%), sulfasalazine (32%) or the IkBa super repressor (26%). The inhibitors alone or the transfection with the super repressor per se had no or only a weak apoptotic effect (5-8% for MG132) (data not shown). In moderately resistant PancTu-1 cells, NF-kB inhibition had a similar chemosensitizing effect as in the highly resistant cell lines. In the sensitive PT45-P1 and T3M4 cells, the strong apoptotic effect of 20 or 0.04 mm gemcitabine was only moderately increased or not affected by the NF-kB inhibition (data not shown). The extent of chemosensitization by NF-kB inhibition was approximately the same if 20 or 0.04 mm gemcitabine was used (data not shown).
Basal Akt activation in pancreatic cancer cell lines did not correlate with gemcitabine resistance
To determine whether Akt is also constitutively activated in these pancreatic cancer cell lines, Akt activation was analysed by immunoblotting using an antibody recognizing the Ser473-phoshorylated form of Akt. Figure 6a shows that T3M4 exibited the highest level of phosphorylated Akt. In PancTu-1, BxPc-3 and PT45-P1 cells, a significantly lower level of phosphorylated Akt was detectable, and in Capan-1 cells almost no basal Akt phosphorylation was found. Unphosphorylated Akt was detectable in all cell lines at a similar level (Figure 6a ). To ensure that the cell lines exhibiting low or no basal phosphorylation of Akt were capable of Figure 3 Time and dose-dependent effects of gemcitabine and VP16 on NF-kB activity. (a) Cells were exposed to 20 mm gemcitabine or VP16 for various periods. At the indicated time, nuclear extracts were prepared and EMSAs for NF-kB binding activity were performed. A representative from four independent experiments is shown. (b) Cells were incubated with the indicated amounts of gemcitabine or VP16 for 6 h. Nuclear extracts were submitted to EMSAs for NF-kB binding activity. A representative from four independent experiments is shown. (c) Cells were transfected with pkBLuc(firefly) together with pTKLuc(renilla). At 16 h after transfection, the medium was replaced and cells were left untreated or treated with the indicated amounts of gemcitabine or VP16 for 6 h. Expression of firefly-luciferase and renilla-luciferase in total cellular extracts (adjusted to equal amounts of protein) was measured. Firefly-luciferase activity was normalized to the amount of renilla-luciferase and the data represent the mean (+/À s.d.) of four independent experiments performed in duplicates Role of NF-jB and PI3K/Akt in gemcitabine resistance A Arlt et al activating Akt, cells were treated with TNFa, IL-1b or PDGF and phosphorylation of Ser473 was analysed. As shown in Figure 6b , in all cell lines an increased Ser473 phosphorylation of Akt was detectable 30 min after stimulation with TNFa, indicating that the Akt signal transduction pathway is intact in these cell lines.
LY294002 inhibited basal and inducible Akt phosphorylation, but had no effect on gemcitabine resistance
To assess the role of activated Akt in the resistance towards gemcitabine exhibited by the pancreatic cancer cell lines used in this study, the effect of the specific Akt inhibitor LY294002 (Brunn et al., 1996; Sekulic et al., 2000) was analysed. As shown in Figure 6b , 25 mm LY294002 completely inhibited basal and TNFa-inducible phosphorylation of Akt. Since some reports indicated that LY294002 has a pro-apoptotic effect on some cancer cell lines (Ng et al., 2000; Brognard et al., 2001) , the effect of single treatment with LY294002 on apoptosis was determined. At a dose of 25 mm of LY294002, only a weak induction of apoptotic cell death (approx. 5-10%) was detectable after 24 h (data not shown). To test whether Akt is involved in the resistance of BxPc-3, Capan-1 and PancTu-1 cells against gemcitabine, these cells were preincubated with 25 mm LY294002 for 3 h, followed by treatment (24 h) with gemcitabine (0.04 mm). Annexin V Figure 4 Inhibition of basal NF-kB activity. (a) Cells were treated for 3 h with 1 mm sulfasalazine, 5 mm MG132 or left untreated. Nuclear extracts were submitted to EMSAs for NF-kB binding activity. A representative from four independent experiments is shown. (b) Cells were transfected with pNFkBLuc(firefly) together with pTKLuc(renilla). At 16 h after transfection, the medium was replaced and cells were treated for 6 h with 1 mm sulfasalazine, 5 mm MG132 or left untreated. Expression of firefly-luciferase and renillaluciferase in total cellular extracts (adjusted to equal amounts of protein) was measured. Firefly-luciferase activity was normalized to the amount of renilla-luciferase and the data represent the mean (+/À s.d.) of four independent experiments performed in duplicates. (c) Cells were transfected with an expression vector for the IkB supper-repressor (SR) or lacZ (mock). At 16 h after transfection, the medium was replaced for 6 h. Nuclear extracts were submitted to EMSAs for NF-kB binding activity. A representative from four independent experiments is shown. (d) Cells were transfected with pNFkBLuc(firefly) together with pTKLuc(renilla) and an expression vector for the IkBa super repressor (SR) or lacZ (mock). At 16 h after transfection, medium was replaced for 6 h incubation. Expression of firefly-luciferase and renilla-luciferase in total cellular extracts (adjusted to equal amounts of protein) was measured. Fireflyluciferase activity was normalized to the amount of renilla-luciferase and the data represent the mean (+/À s.d.) of four independent experiments performed in duplicates 
) of five independent experiments
Role of NF-jB and PI3K/Akt in gemcitabine resistance A Arlt et al staining revealed that all three pancreatic cancer cell lines exhibited only a weak gain of gemcitabine-induced apoptotic cell death if LY294002 was added (Figure 7 ). Higher doses of LY294002 led to a dose-dependent induction of apoptosis per se, but not to a sensitization towards gemcitabine treatment (data not shown).
Akt is not involved in constitutive NF-kB activity of BxPc-3, Capan-1 and PancTu-1 cells Recent reports indicated that PI3 K and Akt are able to trigger NF-kB activation by enhancing the transcriptional activity of the p65 subunit and/or by phosphorylating IkB (Madrid et al., 2000; Reddy et al., 2000) . To determine whether PI3K/Akt is involved in the basal NF-kB activity of BxPc-3, Capan-1 and PancTu-1 cells, these cells were treated for 3 h with LY294002 and NFkB activity was analysed by EMSA and luciferase reporter gene assay. At a dose of 25 mm, LY294002 had no effect on NF-kB binding activity as shown by EMSA (Figure 8a) . Furthermore, at this dose no suppression of NF-kB-dependent transcription occurred (Figure 8b ).
Discussion
The NF-kB and Akt/PI3 K signal transduction pathways are implicated in the resistance of numerous solid tumors against a variety of anticancer drugs (for review Vivanco and Sawyers, 2002; Karin et al., 2002) . In the present study, we elucidated the role of these two anti-apoptotic factors in the sensitivity of human pancreatic cancer cell lines towards gemcitabine treatment. For this study, five ductal pancreatic adenocarcinoma cell lines were used Cells transfected with pNFkBLuc(firefly) together with pTKLuc(renilla) were treated with 25 mm LY294002 for 3 h. Expression of firefly-luciferase and renilla-luciferase in total cellular extracts (adjusted to equal amounts of protein) was measured. Fireflyluciferase activity was normalized to the amount of renillaluciferase and the data represent the mean (+/À s.d.) of four independent experiments performed in duplicates Role of NF-jB and PI3K/Akt in gemcitabine resistance A Arlt et al exhibiting a diverse mutation pattern of important established tumor suppressor genes and proto-oncogenes such as p53, Ki-ras and SMAD/DPC4 (Kalthoff et al., 1993; Moore et al., 2001; Crnogorac-Jurcevic et al., 2002) . Among these cell lines, T3M4 and PT45-P1 cells were highly sensitive towards gemcitabine-induced cell death at a dose between 0.03 and 20 mm. PancTu-1 cells showed only a moderate increase in apoptotic cell death under these conditions, whereas BxPc-3 and Capan-1 cells exhibited almost no induction of apoptosis. Cell cylce analysis revealed a gain of cells in G1/early S phase in all cell lines (data not shown), consistent with one of the actions of gemcitabine as an inhibtor of DNA elongation (Ng et al., 2000; Galmarini et al., 2002) . This indicated that the uptake or intracellular targeting of gemcitabine was not altered in these cell lines, thus excluding a failure of drug uptake or of metabolism as being responsible for the resistance of these cell lines against gemcitabine.
Since the distribution of mutations in p53, Ki-ras or SMAD/DPC4 (Kalthoff et al., 1993; Moore et al., 2001; Crnogorac-Jurcevic et al., 2002) did not correlate with the sensitivity to gemcitabine, other mechanisms suppressing apoptosis had to be responsible for the gemcitabine resistance of BxPc-3, Capan-1 and PancTu-1 cells.
This study shows that one mechanism by which these three cell lines are able to survive gemcitabine treatment relies on an elevated basal NF-kB activity. Previous reports from our laboratory and others (Wang et al., 1999a; Dong et al., 2002) have demonstrated that constitutive NF-kB activity is present in approx 70% of human pancreatic cancer and several pancreatic carcinoma cell lines. This basal NF-kB activity is responsible for the resistance against topoisomerase I (Wang et al., 1999a) and II inhibitors , whereas the drug-induced NF-kB activity is dispensable from the resistant phenotype. The finding that the pattern of resistance towards gemcitabine is identical to that of the topoisomerase-II inhibitors VP16 and doxorubicin indicated that the basal NF-kB activity might also be involved in the resistance against gemcitabine.
This hypothesis was confirmed by the fact that these resistant cell lines could be sensitized towards gemcitabine-induced cell death by pharmacological NF-kB inhibition with sulfasalazine or MG132, as well as by ectopic expression of the IkBa super repressor. Since there are controversial reports whether the basal NF-kB activity Oya et al., 2001; Bian et al., 2002) or the drug-or death-ligand-induced NF-kB activity (Wang et al., 1996; Trauzold et al., 2001 ) is responsible for the chemoresistance of cancer cells, we investigated whether NF-kB was induced by gemcitabine treatment. Irrespective of their chemosensitivity, all cell lines exhibited a dose-dependent induction of NFkB binding activity under treatment with 0.5-20 mm gemcitabine. While treatment with 0.04 mm gemcitabine failed to induce NF-kB activity as shown by EMSA and luciferase assay, it still induced apoptosis in the sensitive cells. The fact that NF-kB inhibition sensitized the resistant cell lines towards gemcitabine at this low dose in a similar fashion as found for 20 mm gemcitabine stressed the hypothesis that the basal NF-kB activity is responsible for gemcitabine resistance. Moreover, since the chemosensitive cell lines T3M4 and PT45-P1 showed no reduction in the number of apoptotic cells if the none NF-kB inducing dose of 0.04 mm gemcitabine was used, a pro-apoptotic role for NF-kB activation, as proposed for some cytotoxic stimuli like superoxide or doxorubicin (Kaltschmidt et al., 2000; Bian et al., 2001) , could be ruled out for gemcitabine treatment.
In contrast to a recent report that indicated a role for Akt/PI3 K in gemcitabine resistance of the pancreatic adenocarcinoma cell lines PK1 and PK8 (Ng et al., 2000) , no such correlation was observed in BxPc-3, Capan-1 and PancTu-1 cells. Among the group of chemoresistant cell lines, only BxPc-3 cells exhibited significant levels of phosphorylated Akt, and in the chemosensitive cell line T3M4 also high levels of phosphorylated Akt were detectable. The other cell lines exhibited only weak or no significant amounts of phosphorylated Akt, and no effect of gemcitabine on Akt phosphorylation was observed (data not shown). Furthermore, treatment with the specific PI3K/Aktinhibitor LY294002 (Brunn et al., 1996; Sekulic et al., 2000) blocked basal (if any were detectable) as well as TNFa-induced Akt phosphorylation in all cell lines, whereas gemcitabine-induced cell death was not enhanced. This controversial finding may be attributed to the high basal NF-kB activity found in BxPc-3, Capan-1 and PancTu-1 cells that turned out to be equally insensitive to PI3K/Akt inhibition. Thus, the high constitutive NF-kB activity that protects these cells from gemcitabine-induced apoptosis is due to mechanisms that do not require activated Akt, i.e., autocrine cytokine production.
The data presented in this study have important implications for subsequent preclinical and clinical studies. The fact that basal NF-kB activity is not only involved in the resistance of pancreatic carcinoma cell lines towards topoisomerase-II inhibitors but also in the resistance towards gemcitabine stresses the central role of this factor as a target for chemotherapy.
Materials and methods

Materials and cell culture
The human pancreatic carcinoma cell lines BxPc-3, Capan-1, PancTu-1, T3M4 and PT45-P1 as well as their handling were described previously (Kalthoff et al., 1993) . For cell culture routine, subconfluent cells were kept in culture (371C, 5% CO 2 , 85% humidity) in RPMI 40 plus 1% glutamine and 10% fetal calf serum (Biochrom; Berlin, FRG). The expression vector for the IkBa super repressor (pcDNA6-DNIkBa) was kindly provided by Dr F Emmerich from the Max-DelbrueckCentre for Molecular Medicine, Berlin. TNFa and sulfasalazine were purchased from SIGMA (Deisenhofen, Germany), etoposide (VP16) from Bristol Myers Squibb (Mu¨nchen, Germany), gemcitabine from Lilly (Bad Homburg, Germany) and LY294002 and MG132 from Biomol (Hamburg, Germany).
Apoptosis assay
Apoptosis was measured by means of the ApoAlert annexin V binding assay (Clontech; Heidelberg, Germany). Briefly, 10 5 cells were pelleted, resuspended in 200 ml of HEPES-buffered saline, and 10 ml of FITC-labelled enhanced annexin V and 100 ng of propidium iodide (PI) were added. Upon incubation for 15 min at room temperature in the dark, samples were brought to 1 ml with PBS. Analysis was done by fluorescence-flow cytometry (Galaxy Argon Plus; Dako, Hamburg, Germany), and the results were analysed using FLOMAX software (Dako). Those cells exhibiting high staining intensity with Annexin V were regarded as being apoptotic.
EMSA
Nuclear extract preparation and EMSAs were performed as described previously (Scha¨fer et al., 1998) . Briefly, 5-10 Â 10 6 cells were washed twice with PBS and then lysed with 250 ml of a hypotonic HEPES/HCl buffer (10 mm, pH 7.6, containing 50 mm KCl, 0.1 mm PMSF, 0.5 mg/ml aprotinin, 0.1 mm dithiothreitol). Nuclei were collected by centrifugation (10 000 r.p.m.; 5 min), washed once with the same buffer and then resuspended in 50-100 ml high-salt HEPES/HCl buffer (50 mm, pH 7.9, containing 0.5 m NaCl, 1 mm MgCl 2 , 0.1 mm PMSF, 0.5 mg/ml aprotinin, 0.1 mm dithiothreitol) followed by 15 min agitation on ice and subsequent centrifugation (10 000 r.p.m.; 15 min). The obtained nuclear extracts (3-5 mg protein) were incubated with a g 32 P-labelled oligonucleotide containing a consensus NF-kB binding site (Promega; Mannheim, Germany). After 30 min incubation at room temperature, samples were submitted to electrophoresis at 150 V, 41C. Gels were dried and exposed to X-ray Hyperfilm (Amersham; Freiburg, Germany). For NF-kB super-shift assay, anti-p65 and -p50 antibodies (Santa Cruz; Heidelberg, Germany) were added (1 h, 41C) prior to electrophoresis.
Western blot analysis
Cells (5-10 Â 10 6 ) were washed twice with PBS and then lysed with 250 ml of a hypotonic HEPES buffer (10 mm, pH 7.6) containing 50 mm KCl, 0.1 mm PMSF, 0.5 mg/ml aprotinin, 0.1 mm sodium orthovanadate. Upon centrifugation, supernatants were adjusted to equal amounts of protein and diluted with one volume of 2 Â SDS-sample buffer and heated for 5 min at 951C. Samples (10 mg protein) were run on 12.5% SDS-PAA gels and electroblotted onto PVDF membrane. Blots were blocked overnight with 5% nonfat milk powder, 0.1% Tween 20 in PBS (blocking solution) at 41C. Afterwards, blots were exposed to an antibody against P-Akt (S473) or Akt (both from Cell Signalling, USA) at a 1000-fold dilution in blocking solution (1 h, room temperature). After extensive washing with blocking solution, blots were exposed to the appropriate secondary antibody and developed using the Phototope immunoblot detection kit (New England Biolabs, USA).
Cell transfection and luciferase reporter assay
Semiconfluent cells grown on six-well plates were serum starved for 2 h and then submitted to lipofection (8 ml/mg DNA Enhancer; 16 ml/mg DNA Effectene, QIAGEN, Hilden, Germany) using 0.2 mg pNF-kB-Luc(firefly) together with 0.2 mg pRLTK-Luc (renilla). After 16 h, medium was replaced and transfectants were further incubated with or without stimuli for 6-8 h. For cell lysis and detection of luciferase activity, a commercial assay kit (Promega; Mannheim, Germany) was used, and luciferase activity was quantified in a Berthold luminometer. Protein concentrations were determined with the Bio-Rad protein assay. Transfection efficacy was checked in parallel by determination of renilla-luciferase expression.
Similarly, cells were lipofected with 0.2 mg/well of an expression plasmid (pCDNA6) encoding DN-IkBa together with 0.2 mg/well pCMV-lacZ or with pCMV-lacZ alone.
Abbreviations NF-kB, Nuclear factor kB; IkB, inhibitor kB; IKK, IkB kinase; FITC, fluorescein isothiocyanate; PMSF, phenyl methansulfonyl fluoride; P13K, P13 Kinase; MDR, multi drug resistance.
